epoprostenol teva ® 0.5 mg
salomon,levin & elstein ltd - epoprostenol as sodium 0.5 mg - powder and solvent for solution for infusion - epoprostenol - epoprostenol teva is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond to conventional therapy.
epoprostenol powder and solvent for solution for infusion 0.5mg
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - epoprostenol sodium - powder and solvent for solution for infusion - epoprostenol sodium 0.531 mg - antithrombotic agents
flolan 0.5mg injection
glaxo wellcome uk limited - epoprostenol sodium - powder and solvent for solution for infusion - epoprostenol sodium 0.5 mg - antithrombotic agents
veletri
actelion registration ltd - epoprostenol - pdr for soln for infusion - 0.5 milligram - epoprostenol
veletri
actelion registration ltd - epoprostenol - pdr for soln for infusion - 1.5 milligram - epoprostenol
flolan 0.5 mg powder and solvent for solution for infusion
glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - epoprostenol sodium - powder and solvent for solution for infusion - epoprostenol sodium 0.5 mg - antithrombotic agents
veletri 1.5 milligram powder for solution for infusion
janssen-cilag international nv - epoprostenol - powder for solution for infusion - 1.5 milligram(s) - platelet aggregation inhibitors excl. heparin; epoprostenol
epoprostenol drehm
drehm pharma gmbh - epoprostenol - pdr+solv for soln for inf - 500 microgram
epoprostenol drehm
drehm pharma gmbh - epoprostenol - pdr+solv for soln for inf - 1.5 milligram
flolan 0.5 mg powder and solvent for solution for infusion
glaxosmithkline (ireland) limited - epoprostenol - powder and solvent for solution for infusion - 0.5 milligram(s) - platelet aggregation inhibitors excl. heparin; epoprostenol